Fierce Biotech
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to $525 million in milestone payments tied to assets in development.